Scarica l'app Stockscreener
13.22
25.07%
2.65
Precedente Chiudi:
$10.57
Aprire:
$12.69
Volume 24 ore:
70,377
Relative Volume:
0.81
Capitalizzazione di mercato:
$35.53M
Reddito:
$28.83M
Utile/perdita netta:
$-13.34M
Rapporto P/E:
-8.6974
EPS:
-1.52
Flusso di cassa netto:
$-7.49M
1 W Prestazione:
+15.76%
1M Prestazione:
+31.02%
6M Prestazione:
+726.25%
1 anno Prestazione:
+307.65%
Intervallo 1D:
$11.29
$13.53
Intervallo di 1 settimana:
$10.06
$13.53
Portata 52W:
$1.44
$36.00
Exicure Inc Stock (XCUR) Company Profile
Nome
Exicure Inc
Settore
Industria
Telefono
847-673-1700
Indirizzo
2430 N. HALSTED ST., CHICAGO, IL
Confronta XCUR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
0.1898 | 398.43M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.73 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.68 | 113.68M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
5.15 | 65.17M | 0 | 0 | 0 | 0.00 |
|
USTB
USAA Core Short-Term Bond ETF
|
50.53 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-12-18 | Iniziato | BMO Capital Markets | Outperform |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
Exicure Inc Borsa (XCUR) Ultime notizie
Exicure secures Australian patent for cancer treatment - Investing.com India
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Business Wire
Exicure announces board member departures, transitions By Investing.com - Investing.com Australia
(XCUR) Technical Pivots with Risk Controls - Stock Traders Daily
Exicure announces board member departures, transitions - Investing.com
Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 16.2% in February - Defense World
Where are the Opportunities in (XCUR) - Stock Traders Daily
Exicure (NASDAQ:XCUR) Stock Price Down 1.6% – Time to Sell? - Defense World
Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes - MSN
How To Trade (XCUR) - Stock Traders Daily
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - Citeline News & Insights
How the (XCUR) price action is used to our Advantage - Stock Traders Daily
Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 17.3% in January - Defense World
Hitron Systems Inc. announced that it expects to receive KRW 30 billion in funding -September 05, 2024 - Marketscreener.com
Exicure Inc (XCUR) requires closer examination - US Post News
Exicure signs purchase agreement with GPCR Therapeutics - MSN
Exicure, back from brink and under new management, buys GPCR's US unit and clinical-stage drug - Fierce Biotech
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. - BioSpace
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. - Yahoo Finance
Exicure announces purchase agreement with GPCR Therapeutics - TipRanks
Exicure Acquires GPCR Therapeutics USA, Signs Major Licensing Deal for Drug Development - StockTitan
Exicure, Inc. (NASDAQ:XCUR) Sees Significant Decrease in Short Interest - Defense World
When (XCUR) Moves Investors should Listen - Stock Traders Daily
Exicure appoints new audit committee members By Investing.com - Investing.com Nigeria
Exicure Secures $8.7 Million in Stock Purchase Deal - MSN
Exicure appoints new audit committee members - Investing.com
Exicure, Inc. (NASDAQ:XCUR) Short Interest Update - Defense World
Exicure Stock Surges On Blood Cancer Portfolio Acquisition Plans, Regaining Nasdaq Compliance: Retail Exuberant - MSN
A Northwestern-born startup has new ownership — and a new focus - Crain's Chicago Business
Exicure Stock Surges On Blood Cancer Portfolio Acquisition Plans, Regaining Nasdaq Compliance: Retail Exuberan - Asianet Newsable
Exicure joins hands with GPCR Therapeutics for growth in biotech (NASDAQ:XCUR) - Seeking Alpha
Exicure signs MOU with GPCR Therapeutics - TipRanks
Exicure (XCUR) to Acquire GPCR USA, Gains Phase 2 Cancer Drug Pipeline with $2B Market Potential - StockTitan
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech - Yahoo Finance
CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes - Business Wire
Exicure Names Andy Yoo as President, CEO - MarketWatch
Exicure Shareholders Approve Major HiTron Equity Financing - TipRanks
Exicure, Inc. Appoints Andy Yoo as Chief Executive Officer - Marketscreener.com
Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive - EIN News
Exicure Secures $12M Strategic Investment as HiTron Systems Takes Majority Stake - StockTitan
Exicure Secures $15M Investment Deal with HiTron Systems Taking Majority Stake - StockTitan
Exicure (NASDAQ:XCUR) Unaudited Proforma Consolidated Balance Sheets Show Growth - Defense World
Exicure boosts equity, eyes Nasdaq compliance - Investing.com
Exicure boosts equity, eyes Nasdaq compliance By Investing.com - Investing.com Australia
Stock market news: Exicure -34.53%, Senti Biosciences -23.70% among biggest losers in early trading - Business Upturn
Exicure Inc Azioni (XCUR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.55%
1.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):